Effect of bimekizumab on patient-reported disease impact in patients with psoriatic arthritis: 1-Year results from two Phase 3 studies
Journal Reference: Rheumatology 2024 Epub ahead of print doi: 10.1093/rheumatology/keae277
Compared with placebo, bimekizumab-treated patients displayed a rapid clinically meaningful improvement in PsAID-12 scores at Week 4, which continued to Week 16 and was sustained to 1 year. Gossec et al. assessed 1-year bimekizumab efficacy from the patient perspective using the PsAID-12 questionnaire in bDMARD-naïve (BE OPTIMAL) and TNFi-IR (BE COMPLETE) patients with active PsA.
Improvements were similar in both bDMARD-naïve and TNFi-IR patients with active PsA, and patients who switched to bimekizumab from placebo at Week 16 achieved similar improvements by Week 52/40. Patients receiving bimekizumab showed a higher proportion of within-patient improvement and favourable disease severity status compared with patients receiving placebo.
